Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
Under a Creative Commons license
open access
Graphical abstract
Intravenous administration of curcumin in combination with paclitaxel was superior to that of the paclitaxel-placebo combination with respect to ORR and physical performance after 12 weeks of treatment in patients with advanced and metastatic breast cancer. Intravenous administration of curcumin yielded no major safety concerns and no reduction in the quality of life but may be beneficial in reducing fatigue.
Keywords
Curcumin
Paclitaxel
Breast cancer
Clinical trial
Abbreviations
AE
adverse event
CRF
case report form
CR
complete response
EC
ethics committee
GCP
Good Clinical Practice
ECOG
Eastern Cooperative Oncology Group
ICD
International Classification of Diseases
DFS
disease-free survival
MBC
metastatic breast cancer
ORR
objective response rate
OR
objective response
PD
progressive disease
PR
partial response
RECIST
Response Evaluation Criteria in Solid Tumors
TTP
time to progression
PFS
progression-free survival
SD
stable disease
TTF
time-to-treatment failure
Cited by (0)
© 2020 The Author(s). Published by Elsevier GmbH.